Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT05986864
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
68
Enrollment
INDUSTRY
Sponsor class
Conditions
Neovascular Age-related Macular Degeneration
Interventions
GENETIC:
SKG0106
Sponsor
Skyline Therapeutics (US) Inc.